14 Assessing and managing lupus arthritis

evaluation in randomized controlled trials to establish efficacy, safety, and long-term outcomes.Case 1: A 52-year-old patient with DLE A 52-year-old female with refractory DLE was treated orally with FAEs, consisting of 30 mg dimethyl fumarate and 75 mg monoethyl fumarate salts per tablet, administered at a dose of 1-3 tablets per day. 5After 6 months of treatment, the Revised Cutaneous Lupus Disease Area and Severity Index (RCLASI) scores improved significantly.The disease relapsed after discontinuation but improved upon re-initiation, supporting FAEs as a promising option in therapy-resistant DLE. 5. Discuss risk factors for drug-induced CLE .Discuss treatment paradigm for refractory CLE .Review new therapeutic approaches for CLE